Core Viewpoint - Hanbang Technology's stock experienced a 1.60% increase on September 8, with a trading volume of 73.06 million yuan, indicating positive market sentiment towards the company [1]. Financing Summary - On September 8, Hanbang Technology had a financing buy-in amount of 6.97 million yuan, with a net financing purchase of 1.07 million yuan after 5.90 million yuan in financing repayments [1]. - The total financing and securities balance for Hanbang Technology reached 93.73 million yuan, accounting for 12.06% of its market capitalization [1]. - There were no securities sold or repaid on that day, indicating no short-selling activity [1]. Company Overview - Hanbang Technology, established on October 28, 1998, is located in Huai'an Economic and Technological Development Zone, Jiangsu Province [1]. - The company specializes in providing professional separation and purification equipment, consumables, application technology services, and related technical solutions for the pharmaceutical and life sciences sectors [1]. - The revenue composition of Hanbang Technology includes 70.99% from small molecule drug separation and purification equipment, 22.94% from large molecule drug separation and purification equipment, and 6.07% from other sources [1]. Financial Performance - As of June 30, 2025, Hanbang Technology reported a total revenue of 349 million yuan, reflecting a year-on-year growth of 5.99% [2]. - The net profit attributable to the parent company was 27.80 million yuan, showing a year-on-year decrease of 26.24% [2]. - The number of shareholders decreased by 48.43% to 9,372, while the average circulating shares per person increased by 93.92% to 1,764 shares [2]. Shareholding Structure - As of June 30, 2025, the largest circulating shareholder of Hanbang Technology is Dongfanghong Medical Upgrade Stock Initiation A (015052), holding 483,700 shares as a new shareholder [2].
汉邦科技9月8日获融资买入697.29万元，融资余额9373.02万元